Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
34.1M
-
Shares change
-
-2.18M
-
Total reported value, excl. options
-
$313M
-
Value change
-
-$20.3M
-
Put/Call ratio
-
0.63
-
Number of buys
-
59
-
Number of sells
-
-51
-
Price
-
$9.18
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2021
134 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2021.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.1M shares
of 49.6M outstanding shares and own 68.61% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.77M shares), VANGUARD GROUP INC (3.59M shares), BlackRock Inc. (3.07M shares), FRED ALGER MANAGEMENT, LLC (2.99M shares), Camber Capital Management LP (2.73M shares), RENAISSANCE TECHNOLOGIES LLC (1.6M shares), STATE STREET CORP (1.53M shares), Palo Alto Investors LP (1.39M shares), GREAT POINT PARTNERS LLC (1.3M shares), and ACADIAN ASSET MANAGEMENT LLC (1.23M shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.